# A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.

> **NCT07903415** · PHASE1 · RECRUITING · sponsor: **Pfizer** · enrollment: 280 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Esophageal Cancer
- Carcinoma, Non-Small-Cell Lung (NSCLC)
- Gastric Carcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** PF-08098488

## Key facts

- **NCT ID:** NCT07903415
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-29
- **Primary completion:** 2031-01-26
- **Final completion:** 2032-01-26
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2026-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07903415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07903415, "A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07903415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
